From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

In an effort to become more nimble, some companies, like Bayer Pharmaceutical, are getting rid of middle managers.

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...